 SAN CARLOS, Calif., Aug. 11, 2021 GLOBE NEWSWIRE -- Atreca, Inc. Atreca NASDAQ: BCEL, a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the second quarter ended June 30, 2021, and provided an overview of recent developments. 